CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,425 enrolled
Drug / intervention
20vPnC +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04875533
NCT04875533Phase 3Completed
CompareCT.gov

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 60 YEARS OF AGE AND OLDER IN JAPAN, KOREA, AND TAIWAN

Pfizer·interventional·Posted May 6, 2021·Updated Nov 5, 2024

In Brief

A Phase 3 clinical trial evaluating 20vPnC, Saline, and 2 other interventions for Pneumococcal Disease. Completed, enrolled 1,425 participants across 28 sites in 3 countries.

Detailed Summary

A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japan, Korea, and Taiwan

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesJapan, South Korea, Taiwan
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 6, 2021
Enrollment StartJun 14, 2021
Primary CompletionMay 13, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.2 years ago

Interventions

20vPnCbiological

20vPnC

Salineother

Saline

13vPnCbiological

Pneumococcal conjugate vaccine

PPSV23biological

Pneumococcal polysaccharide vaccine